Thank you to Jacqui Straxx for the info on PPML.
The AUA posted the following snip:
The study began in 1995...In 2000, the study was restricted to favorable risk disease. Definitive intervention was offered to those patients with a PSA doubling time of less than three years, Gleason score progression (to 4+3 or greater) or unequivocal clinical progression. Of the 453 patients on the program:
- Median age is currently 70
- Median follow-up is 7.2 years
- Overall survival is 83%
- Prostate cancer survival is 99%.
- 35% (roughly 1 out of 3 patients) have been reclassified as higher risk and offered definitive therapy.
- 5 of the 453 patients have died of prostate cancer
The most common indications for treatment were a PSA doubling time of less than three years or Gleason upgrading. Of the 137 patients treated surgically, the PSA failure rate (rising PSA) was 52 percent. Patients with biochemical failure after radical therapy constitute 15 percent of the overall study group. The ratio of non-prostate cancer to prostate cancer mortality was 16.
Full article posted in PSA Rising: